GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (XPAR:ALMDP) » Definitions » EBIT per Share

Medesis Pharma (XPAR:ALMDP) EBIT per Share : €-0.88 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Medesis Pharma EBIT per Share?

Medesis Pharma's EBIT per Share for the six months ended in Dec. 2023 was €-0.52. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.88.

During the past 3 years, the average EBIT per Share Growth Rate was -53.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was -35.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Medesis Pharma's EBIT per Share or its related term are showing as below:

XPAR:ALMDP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -57.8   Med: -53.9   Max: -37.2
Current: -53.9

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Medesis Pharma was -37.20% per year. The lowest was -57.80% per year. And the median was -53.90% per year.

XPAR:ALMDP's 3-Year EBIT Growth Rate is ranked worse than
90.64% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs XPAR:ALMDP: -53.90

Medesis Pharma's EBIT for the six months ended in Dec. 2023 was €-2.56 Mil.


Medesis Pharma EBIT per Share Historical Data

The historical data trend for Medesis Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma EBIT per Share Chart

Medesis Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial -0.19 -0.23 -0.73 -0.72 -0.84

Medesis Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 -0.42 -0.30 -0.36 -0.52

Medesis Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Medesis Pharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.141/4.960
=-0.83

Medesis Pharma's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

EBIT per Share(Q: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.556/4.960
=-0.52

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medesis Pharma  (XPAR:ALMDP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Medesis Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Medesis Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medesis Pharma Business Description

Traded in Other Exchanges
Address
Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670
Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines